Background
==========

Onset of action is recognized as an important pharmacologic property of allergic rhinitis medications and can be reliably determined under the controlled conditions of the Environmental Exposure Unit (EEU).

Objective
=========

To evaluate the onset of action of loratadine/montelukast (10 mg/10 mg) versus placebo in subjects with ragweed-induced seasonal allergic rhinitis (SAR).

Methods
=======

A single-center, double-blind, parallel-group study of ragweed-sensitive allergic rhinitis subjects (N=310), performed in the EEU. Subjects were exposed to ragweed pollen in the EEU and symptoms were recorded at 30, 60, 90, and 120 minutes prior to a single dose of loratadine/montelukast or placebo. After dosing, symptoms were recorded for 4 hours - at 15-minute intervals for the first 2 hours and 30-minute intervals for the final 2 hours. The primary endpoint was the time to onset of action for loratadine/montelukast, defined as the first time point at which the mean change from baseline in total symptom score (TSS) for loratadine/montelukast became and remained significantly better than placebo. Secondary endpoints included nasal congestion scores and peak nasal inspiratory flow (PNIF).

Results
=======

The onset of action of loratadine/montelukast for TSS was 1 hour 15 minutes (p=0.005 versus placebo). Loratadine/montelukast reduced nasal congestion as indicated by significant improvements in both the nasal congestion score (p=0.011) and PNIF measurements (p=0.007) within 1 hour 15 minutes post dose. The incidence of treatment-emergent adverse events was similar between groups.

Conclusion
==========

The onset of action following treatment with loratadine/montelukast was 1 hour 15 minutes for TSS, as well as for nasal congestion. Loratadine/montelukast was well tolerated.
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